After it was decided to postpone talks between the Indonesian government and the House of Representatives (DPR) about the tax amnesty bill (talks have been postponed until April 2016), the government is in need of formulating a new tax revenue target as the late implementation of the tax amnesty program could mean the government will miss out on tens of trillions of rupiah (billions of US dollars) in tax revenue this year. Indonesia's tax amnesty bill, proposed last year, will make it easier for tax evaders to come clean and repatriate their funds into Indonesia.

Lanjut baca ›

On 28 February 2016, Indonesia Investments released the latest edition of its newsletter. This free newsletter, which is sent to our subscribers once per week, contains the most important news stories from Indonesia that have been reported on our website over the last seven days. Most of the topics involve economic matters such as Indonesia's 11th economic policy package, the mineral ore export ban, the automotive industry, financial results of Astra International and Kalbe Farma, radical Islam, hot money, and more.

Lanjut baca ›

Despite car sales having slowed significantly in Indonesia, there are at least three automotive companies eager to invest a combined IDR 21 trillion (approx. USD $1.6 billion) to expand production capacity in Indonesia this year (either by establishing a new factory or enhancing production capacity at existing plants). In 2015 car sales in Indonesia fell 16.1 percent (year-on-year) to 1.01 million vehicles, the nation's lowest car sales figure since 2011. However, Indonesia remains the second-largest car market and producer in the ASEAN region, after Thailand.

Lanjut baca ›

Indonesia's largest pharmaceutical company, Kalbe Farma, felt the impact of macroeconomic headwinds. The company, one of the largest public pharmaceutical companies in Southeast Asia, today announced its indicative performance (unaudited) for the year 2015. While its net sales grew 3 percent year-on-year (y/y) to IDR 17.4 trillion (approx. USD $1.3 billion), the company's net income fell 4.3 percent (y/y) to IDR 1.98 trillion (approx. USD $147 million). Kalbe Farma's performance in 2015 was plagued by weaker purchasing power in Indonesia and the depreciated rupiah exchange rate.

Lanjut baca ›